Psilocybin Therapy for Depression: Who Responds Best?

Psilocybin & Depression

59 patients

In 59 patients from the Imperial College psilocybin trial, how much the brain 'opened up' after treatment predicted antidepressant outcomes at six months, a change that escitalopram never produced.

Carhart-Harris et al., Nature Medicine, 2022

Oceanic boundlessness

the session quality that most strongly predicted antidepressant outcome in 20 TRD patients

5-HT2A downregulation

how SSRIs blunt psilocybin's therapeutic effects in current antidepressant users

233 patients

in the largest Phase 2b TRD trial confirming 25mg as the most effective dose

Carhart-Harris et al., Nature Medicine, 2022

View as image ↗

Before a patient with depression takes a single milligram of psilocybin, a brain scan can now predict whether they are likely to respond to treatment. That finding, published in Biological Psychiatry in 2024, identified a specific measure of connectivity between the amygdala and the prefrontal cortex as the first validated imaging biomarker for psilocybin treatment selection.^[1]

The question of who responds to psilocybin therapy for depression is not just academic. Across Phase 2 clinical trials, response rates ranged from 37 to 71%, which means 30 to 63% of participants in any given trial did not respond. The broader evidence for psilocybin as an antidepressant is covered in our guide to psilocybin for major depression. What those response rates don't answer is whether the non-responders could have been identified in advance.

Three categories of predictors have emerged from the research. What is happening in the brain before treatment starts. What the patient experiences during the session. And how much the brain changes in the hours and days after the dose.

The Brain Scan That Predicts Your Response Before Treatment Starts

Aaronson and colleagues set out to answer one of the most practical questions in psilocybin research: could brain imaging before treatment identify patients likely to respond?

They analyzed resting-state fMRI scans taken from patients with depression before they received psilocybin therapy. The measure that predicted response was connectivity between the amygdala and the anterior cingulate cortex (ACC). The amygdala is the brain's primary center for emotional reactivity and threat detection. The ACC is the region that links emotional responses to rational decision-making. Patients with lower connectivity between these two regions at baseline tended to respond better to psilocybin.^[1]

This may seem counterintuitive. If these two regions handle emotional regulation, why would lower connectivity between them predict a better treatment outcome?

The working hypothesis is that psilocybin works partly by disrupting rigid communication patterns in brain circuits involved in emotional processing. In depression, the amygdala tends to over-signal threat and negative emotion. If the connection between the amygdala and ACC is already lower at baseline, psilocybin may have more room to produce its characteristic loosening of those fixed patterns and open space for more flexible ones to emerge.

This was the first study to validate an fMRI-based biomarker specifically for psilocybin treatment selection. That matters because antidepressant prescribing is largely trial-and-error. If the amygdala-ACC finding replicates in larger cohorts, it could eventually support a brain-scan-based screening step for psilocybin therapy. That replication has not happened yet, and the finding should be treated as preliminary.

The Session Experience That Predicts Recovery, and the One That Does Not

The amygdala-ACC predictor operates before treatment. A second category of predictors emerges during the session itself.

Roseman and colleagues studied 20 patients with treatment-resistant depression who received psilocybin in an open-label trial.^[2] After each session, patients completed detailed questionnaires about the quality of their experience. The researchers then looked at which dimensions of the psychedelic experience predicted antidepressant outcomes weeks later.

The strongest predictor of better outcomes was a quality called oceanic boundlessness. This refers to the sense of ego dissolution, deep meaningfulness, and unity with the surrounding environment that many patients report during a psychedelic experience. Patients who rated this dimension higher had significantly better antidepressant results. Patients who experienced more fear, paranoia, or disorientation during the session had worse outcomes.

This finding matters for how psilocybin therapy is designed and conducted. "Set and setting" (the patient's mental and emotional state going in, and the physical environment during the session) are not merely comfort measures. They appear to be active variables in the antidepressant outcome. A session that slides into anxiety and resistance does not just feel worse. It may produce weaker therapeutic results.

The session experience predictor connects to the brain-level evidence discussed in the next section. A 2022 study in Nature Medicine found that psilocybin uniquely increased functional connections across the entire brain while escitalopram produced no such change.^[3] The oceanic boundlessness state may partly reflect this connectivity shift as it unfolds during the session, though the direct imaging link between in-session experience and connectivity change has not been established in a single study.

After the Dose: How Much Your Brain 'Opens Up' Predicts Six-Month Outcome

The third category of predictors operates in the days after the session, not before or during it.

Carhart-Harris and colleagues analyzed fMRI scans from 59 patients enrolled in the Imperial College escitalopram trial, the head-to-head comparison of psilocybin versus escitalopram published in the New England Journal of Medicine.^[3] In the fMRI sub-study, psilocybin therapy produced a distinctive change in how brain regions communicated with each other. Previously isolated brain networks began working together. Global connectivity across the brain increased.

The key finding for predicting response was this: how much that connectivity increased after psilocybin predicted how well the patient did at six months. Patients with larger connectivity increases had better antidepressant outcomes. Escitalopram produced none of this. The antidepressant showed no measurable change in global brain integration.

This helps answer why two patients who receive the same dose of psilocybin can have meaningfully different outcomes. The degree to which their brains respond to the drug, at the level of network-wide connectivity, varies between individuals. Dose alone does not determine response.

A 2024 preclinical study found that psilocybin activates a growth pathway in the brain called TrkB, triggered by a protein called BDNF. This activation promotes the formation of new connections between neurons.^[4] SSRIs work through a different mechanism: they block the reuptake of serotonin at the synapse but do not activate the same structural growth pathways. This helps explain both psilocybin's faster antidepressant onset (days rather than weeks) and its more global effect on brain connectivity. It also helps explain why some individuals' brains respond more strongly to psilocybin than others, at a structural level.

If You're on an SSRI, You May Already Be a Weaker Candidate

For many people considering psilocybin therapy for depression, the most immediately practical predictor is current antidepressant use.

Hendin and colleagues studied patients who received psilocybin while currently taking or recently having taken SSRIs or SNRIs.^[5] The finding was consistent: SSRIs blunt psilocybin's effects. Patients on antidepressants reported weaker subjective experiences and showed smaller therapeutic improvements than patients who were drug-free.

The mechanism is 5-HT2A receptor downregulation. SSRIs increase the amount of serotonin available in the synaptic space (the gap between neurons where chemical signals pass). Over time, the brain responds to this higher serotonin level by reducing the number and sensitivity of the receptors that serotonin binds to. Psilocybin works primarily through one subtype of those receptors, called 5-HT2A. Fewer active receptors means less for psilocybin to work with.

This effect persists for weeks after stopping an SSRI, because the receptors take time to return to baseline density and sensitivity. Clinical protocols for psilocybin therapy typically require patients to taper off SSRIs before the treatment session, though the optimal duration of that washout period has not been precisely established in controlled studies.

There is a somewhat counterintuitive implication here: the patients most likely to be seeking psilocybin therapy (those who have tried and failed multiple antidepressants) are also the most likely to have suppressed 5-HT2A receptor function from prior treatment. How the two treatments differ mechanistically is covered in depth in how psilocybin treats depression differently than SSRIs.

The EPISODE Null Result: What a Failed Trial Reveals About Patient Selection

Understanding who responds to psilocybin requires understanding where the therapy failed, not just where it worked.

Mertens and colleagues ran EPISODE, a Phase 2b active-placebo-controlled trial of psilocybin for treatment-resistant major depression.^[6] Active-placebo designs are more rigorous than standard placebo controls because they give all participants a drug that produces some psychoactive effect, reducing the likelihood that patients can guess whether they received the experimental drug.

EPISODE failed its primary endpoint. The main outcome measure showed no statistically significant difference between the psilocybin group and the active control (adjusted odds ratio of 1.73, p=0.19). However, secondary outcomes did show clinically meaningful effects in some patients, which means some participants responded. The failure at the primary level may reflect how patient selection and trial design interact with statistical power: if response is concentrated in a subgroup, a broad-enrollment trial can be statistically underpowered to detect it.

EPISODE also reported a safety signal worth noting: 4% of patients in the psilocybin group reported suicidal ideation on dosing days, compared to 1 to 2% in the comparator group. This rate is higher than in most earlier psilocybin trials, where suicidal ideation was actually reduced following treatment. Whether this reflects patient characteristics, trial design, or a real subgroup-level risk remains unresolved.

The COMP360 Phase 2b trial, by contrast, enrolled 233 patients with treatment-resistant depression using more standardized eligibility criteria and found a clear dose-response relationship: 25mg of psilocybin produced significantly better antidepressant effects than a 1mg active control, with effects emerging within three weeks.^[7]

The full results from all major psilocybin clinical trials are reviewed in psilocybin for depression: results from the largest clinical trials. For a look at what the evidence shows specifically for patients who have not responded to multiple prior treatments, see psilocybin for treatment-resistant depression: when nothing else works.

Who Responds to Psilocybin Therapy for Depression: Research-Based Predictors

Based on the studies above, the following factors appear in peer-reviewed research as predictors of psilocybin response. Each comes with caveats about sample sizes. These are group-level findings, not individual forecasts.

Factors associated with better response:

1. Lower amygdala-ACC connectivity on baseline fMRI. Patients whose amygdala and anterior cingulate cortex showed lower baseline connectivity on resting-state brain imaging responded better in Aaronson's 2024 cohort. This is the first validated imaging predictor for psilocybin treatment selection; replication in larger samples is needed.^[1]

2. High oceanic boundlessness during the session. Patients who experienced more ego dissolution, unity, and deep meaningfulness during the psychedelic session had significantly better antidepressant outcomes in Roseman's 2017 cohort of 20 TRD patients. The anxious, resistant session predicted the opposite.^[2]

3. Larger post-dose increase in global brain connectivity. The magnitude of brain-wide connectivity increase after psilocybin, measured with fMRI in 59 patients, predicted six-month antidepressant response. Patients whose brains showed more connectivity change after the dose did better months later.^[3]

Factors associated with weaker response:

4. Current SSRI or SNRI use. Patients on antidepressants at the time of psilocybin treatment consistently showed blunted subjective and therapeutic responses, due to reduced 5-HT2A receptor availability. Tapering before treatment may restore psilocybin sensitivity, though the optimal washout period is uncertain.^[5]

5. Broad-enrollment trial designs without targeted patient selection. This is a research observation rather than a clinical predictor, but the EPISODE trial's null primary result illustrates that response detection is sensitive to who is enrolled and how the trial is structured.^[6]

What predictor research cannot yet tell us:

Individual-level prediction of psilocybin response is not yet clinically validated. No test or brain scan available outside a research setting can reliably tell a specific patient whether psilocybin will work for them. The amygdala-ACC finding needs replication. The session experience predictor is partly post-hoc (it's measured during treatment, not before it). The brain connectivity predictor requires a post-treatment fMRI, making it a measure of why treatment worked rather than a tool for deciding whether to proceed.

For patients who respond and achieve remission, how long those effects last is a separate question answered in one dose of psilocybin for depression: how long do effects last. For a companion look at what predicts whether remission holds over months, see sustained remission after psilocybin: what predicts it. For readers not ready for psilocybin who are interested in mood support from non-psychedelic mushrooms, functional mushrooms for depression covers what the evidence shows for lion's mane and reishi.

The Bottom Line

Three categories of predictors for psilocybin response in depression have emerged from peer-reviewed research: lower amygdala-ACC connectivity on baseline fMRI (Aaronson et al., 2024), higher oceanic boundlessness during the session (Roseman et al., 2017), and larger post-dose increases in global brain connectivity (Carhart-Harris et al., Nature Medicine, 2022). Current SSRI use is a consistent negative predictor, driven by 5-HT2A receptor downregulation. These are group-level findings from trials of 20 to 233 patients. Individual-level prediction of psilocybin response is not yet clinically validated.

Frequently Asked Questions

Who is a good candidate for psilocybin therapy for depression?

Based on current research, patients with lower amygdala-ACC connectivity on baseline fMRI, no current SSRI use (or a completed taper), and the capacity to engage with an intense psychedelic experience tend to respond better. Most clinical trials enrolled patients with moderate-to-severe depression or treatment-resistant depression who had not responded to prior antidepressants. Standard trial exclusions include personal or family history of psychosis and bipolar I disorder, based on safety protocols rather than specific predictor data.

What predicts a good response to psilocybin?

Three types of predictors have emerged from peer-reviewed studies. Before treatment: lower connectivity between the amygdala and anterior cingulate cortex on resting-state fMRI predicted better response in a 2024 Biological Psychiatry study (Aaronson et al.). During treatment: higher levels of oceanic boundlessness (ego dissolution, unity, and deep meaningfulness) predicted better outcomes in 20 TRD patients (Roseman et al., 2017). After treatment: larger increases in global brain connectivity measured by fMRI predicted six-month antidepressant response in 59 patients (Carhart-Harris et al., Nature Medicine, 2022).

Does psilocybin work for everyone with depression?

No. Across Phase 2 trials, response rates ranged from 37 to 71%, meaning a substantial proportion of participants in any given trial did not respond. The EPISODE 2026 trial failed its primary endpoint entirely in a treatment-resistant population. Psilocybin appears most effective in patients who show certain baseline brain connectivity patterns, respond strongly to the session experience, and are not currently on SSRIs. Non-responders are currently difficult to distinguish from responders without conducting the full treatment course.

What factors affect psilocybin treatment outcomes?

Baseline brain state (amygdala-ACC connectivity), the quality of the psychedelic session (oceanic boundlessness versus anxiety and fear), post-dose brain connectivity changes, concurrent antidepressant use, and dose all affect outcomes. Across multiple large trials, 25mg has consistently outperformed lower doses. The setting and psychological support during the session also appear to affect treatment quality, connecting to session experience as a predictor of outcome.

Does your brain type affect psilocybin response?

The evidence suggests yes. A 2024 study found that lower connectivity between the amygdala (the brain's emotional reactivity center) and the anterior cingulate cortex (the region connecting emotion to rational thinking) before treatment predicted better psilocybin response. Separately, how much brain-wide connectivity increased after psilocybin predicted six-month outcomes in 59 patients. These findings indicate that individual differences in brain organization and reactivity influence how much therapeutic benefit a given patient receives.

Does taking antidepressants affect psilocybin therapy results?

Yes, consistently. SSRIs and SNRIs reduce the number and sensitivity of 5-HT2A receptors over time, and psilocybin works primarily through these receptors. Patients currently taking SSRIs or SNRIs show blunted subjective effects and smaller therapeutic responses to psilocybin. Clinical protocols for psilocybin therapy typically require patients to taper off antidepressants before treatment, though the optimal washout duration has not been precisely established in controlled studies.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.